Document:

Correction to First Amendment to Lease Agreement

 EXHIBIT 10.8 
  
 CORRECTION TO FIRST AMENDMENT TO LEASE AGREEMENT 
  
 This CORRECTION TO FIRST AMENDMENT TO LEASE AGREEMENT is effective as of January 14, 2005 by and between AGF
VALLEY VIEW, LTD., a Texas limited partnership (“Landlord”) and MONITRONICS INTERNATIONAL, INC., a Texas corporation (“Tenant”). 
  

RECITALS 
  
 A. Landlord and Tenant entered into a Lease Agreement dated May 3, 2004 (the “Lease”). 
  
 B. Landlord and Tenant entered into a First Amendment to Lease Agreement
dated January 14, 2005 (the “First Amendment”). 
  
 C. The First Amendment fails to state the duration of the Lease Term, although the parties intended that the Lease Term continue through the period for payment of Base Rental set forth in the First Amendment. 
  
 D. Landlord and Tenant wish to correct the First Amendment as set forth
herein. 
  
 NOW,
THEREFORE, for valuable consideration, the parties agree as follows: 
  
 1. Terms defined in the Lease and the First Amendment have the same meaning when used in this Agreement, unless a different definition is given.

  
 2. Landlord and Tenant agree that the Lease Term expires
May 31, 2015. 
  
 3. Except as corrected hereby, the Lease
and the First Amendment shall remain in full effect and this Correction shall be binding upon Landlord and Tenant and their respective successors and assigns. 
  

[SIGNATURES ARE ON SEPARATE PAGES] 
  

 Page 1 

 EXECUTED to be effective as of the date shown above. 
  

					
	LANDLORD:
	
	 AGF VALLEY VIEW, LTD.,
 a Texas
limited partnership

		
	By:	 	Skyrise Properties, LLC, a Texas
	 	 	limited liability company,
	 	 	its sole General Partner
			
	 	 	By:	 	 /s/ Leora Azoulay-Lesh

	 	 	 	 	Leora Azoulay-Lesh
	 	 	 	 	Vice President of
	 	 	 	 	Skyrise Properties, LLC

  

 Page 2 

			
	TENANT:
	
	 MONITRONICS INTERNATIONAL, INC.,
 a
Texas corporation

		
	By:	 	 /s/ Stephen M. Hedrick

	Name:	 	Stephen M. Hedrick
	Title:	 	V.P. - Finance

  

 Page 3Fourth Amendment to Lease Agreement

 Exhibit 10.9 
  
 FOURTH AMENDMENT TO LEASE AGREEMENT 
  
 This FOURTH AMENDMENT TO LEASE AGREEMENT (the “Amendment”) is entered into on September 6, 2005, between
MRP/VV, L.P., a Delaware limited partnership (“Landlord”), MONITRONICS INTERNATIONAL, INC., (“Tenant”). 
  
 RECITALS: 
  
 A. Tenant is leasing Premises known as Suite 815 containing 4,550 square feet of Net Rentable Area; Suite 821 containing 8,037 square feet of Net Rentable Area; Suite 825
containing 1,936 square feet of Net Rentable Area; and Suite 829 containing 6,043 square feet of Net Rentable Area totaling 20,566 square feet of Net Rentable Area in Building 8 of the property known as Valley View Tech Center, located at 12801 N.
Stemmons Freeway in Farmers Branch, Texas, under the terms of the Lease Agreement dated December 4, 1991 (the “Lease”) and as amended under the First Amendment Of Lease dated February 17, 1997, (“First Amendment”); the
Second Amendment Of Lease dated September 17, 1997 (“Second Amendment”); and the Third Amendment Of Lease dated August 31, 2001 (“Third Amendment”). 
  
 B. Landlord and Tenant desire to reduce the Premises by the space (the “Reduction Space”) known as Suite 815 containing
4,550 square feet of Net Rentable Area and Suite 829 containing 6,043 square feet of Net Rentable Area of the Building as described on the floor plan attached to this Amendment as Exhibit A. 
  
 C. Landlord and Tenant now desire to extend the term of the Lease. 
  
 NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of
which are acknowledged, Landlord and Tenant amend the Lease as follows: 
  
 1.
The term of the Lease, which was to expire December 31, 2005, is extended to expire February 28, 2011. 
  
 2. On the “Effective Date” of January 1, 2006, Tenant will surrender possession of the Reduction Space to Landlord in the condition that would otherwise be required under the Lease with respect to the
Premises at the end of the term. On and after the Effective Date, the Reduction Space will no longer be a part of the Premises. Upon the Effective Date, all references in the Lease to the “Premises” will designate Suites 821 and 825 in the
Building containing a total of 9,973 square feet of Net Rentable Area (“Renewal Space”) consisting of the area described on Exhibit B. 
  
 3. Beginning on the Effective Date, the Base Rent will be modified pursuant to the table below. Base Rent as so modified will be payable in monthly installments as
otherwise provided in the Lease. 
  

									
	 PERIOD

	  	# OF MONTHS

	  	ANNUAL RATE PER RSF

	  	MONTHLY INSTALLMENT

	 1/1/2006 to 2/28/2006
	  	2	  	$	0.00	  	$	0.00
	 3/1/2006 to 2/28/2011
	  	60	  	$	8.50	  	$	7,064.21

  
 4. Tenant shall lease the Renewal
Space on an “As-ls” basis and shall incur all costs associated with demising the space between Suites 815 and 829 to include construction costs of the demising walls to deek and separating all utilities including electricity, lighting,
HVAC and mechanical services. 
  
 5. Adjustments to Base Rent pursuant to
Paragraph 6 of the Lease for any period before the Effective Date will not be affected by this Amendment. Beginning on the Effective Date, adjustments to Base Rent pursuant to Paragraph 6 of the Lease will be calculated based on Taxes, Insurance,
and Common Area Maintenance Costs that will equal the Taxes, Insurance and Common Area Maintenance Costs per square foot of Net Rentable Area for the calendar year of 2005 gross up to 95% occupancy. In all other respects, adjustments to Base Rent
will continue to be calculated and paid as currently provided in the Lease. 
  
 6.
Effective on the Effective Date, the Third Amendment Of Lease, Parking, Paragraph 5 is hereby amended to decrease the number of vehicles authorized to park in the general parking area to 22 non-reserved surface parking spaces and 6 reserved surface
parking spaces. No parking charges shall apply to the vehicles in the general parking area. 
  
 7. Rider 1, Renewal Option, attached hereto is incorporated and made part of the Amendment. 
  
 8. Landlord’s suite address under the Lease is changed to: 
  
 Stream Realty Partners 
 Attention: Helen
Rivero 
 2200 Ross Avenue, Suite 5400 

 IN WITNESS WHEREOF, Landlord and Tenant have executed and delivered this Amendment. 
  

			
	LANDLORD:
	
	MRP/VV, L.P., a Delaware limited partnership
		
	By:	 	MRP/GP, L.L.C., a Texas limited liability company, general partner
	By:	 	Stream Realty Partners, L.P. is authorized agent
	By:	 	(illegible), L.L.C. its sole G. P.
		
	BY:	 	 /s/ Helen Rivero

	NAME:	 	Helen Rivero
	TITLE:	 	V.P.
	DATE:	 	9.7.05
	
	TENANT:
	
	Monitronics International, Inc.
		
	BY:	 	 /s/ Stephen M. Hedrick

	NAME:	 	STEPHEN M. HEDRICK
	TITLE:	 	V. P. FINANCE
	DATE:	 	9/6/05

 EXHIBIT A 
  

REDUCTION SPACE 
 

 
  
  

 EXHIBIT B 
  

RENEWAL SPACE 
 

 
  
  

 RIDER 1 
  
 RENEWAL OPTION 
  
 Provided this Lease is then in full force and effect and no Event of Default shall have occurred and be continuing, Tenant has one (1) option to
renew the term of this Lease for an additional term of five (5) years on the same terms and conditions contained in this Lease except that the Base Rental be paid under this Lease for the renewal term shall be at the then prevailing market
rental rate for office/showroom space of similar quality and similar size and location. The renewal option shall be exercised only by Tenant’s giving written notice to Landlord at least six (6) months before the expiration of the current
Terms of this Lease. If Tenant fails to deliver to Landlord written notice of the exercise of the renewal option within the prescribed time period, the renewal option shall lapse. Any assignment or subletting by Tenant pursuant to this Lease, other
than an assignment or subletting that does not require Landlord’s consent, shall terminate the renewal option.Severence Letter

 Exhibit 10.1 
  
 December 4, 2003 
  
 Graham P. Allaway, Ph.D. 
 14205 White Water Way 
 Darnestown, Maryland 20878 
  

	Re:	Severance Agreement 

  
 Dear Graham: 
  
 This letter sets forth the terms
and conditions of the severance benefits that will be provided to you by Panacos Pharmaceuticals, Inc. (the “Company”) in the event your employment is terminated by the Company for a reason other than Cause, or in the event
you voluntarily resign for a Good Reason, as those terms are defined below (a “Qualifying Termination”). No severance benefits will be provided upon your termination for Cause or your voluntary resignation (for other than a
Good Reason). Except as provided herein, no severance benefits will be provided upon your death or termination due to a disability, as determined by the Company in its reasonable discretion. No severance will be provided upon your termination in
connection with the Company’s dissolution or cessation of operations without the establishment of a successor entity. This letter shall be referred to as the “Agreement” herein. For the purposes hereof, the
“Trigger Date” shall mean the earlier of (i) the closing of a financing transaction (or series of related financing transactions) in which the Company raises at least $10 million or (ii) the closing of a sale of all
or substantially all of the Company’s assets or a merger, consolidation or reorganization of the Company with or into another corporation or other legal person other than a merger, consolidation or reorganization in which more than fifty
percent (50%) of the combined voting power of the then outstanding securities of the surviving entity (or if more than one entity survives the transaction, the controlling entity) immediately after such a transaction are held in the aggregate
by holders of voting securities of the Company immediately prior to such transaction or (iii) December 31, 2004. 
  
 1. Severance Benefits. Although the Company has no general policy or procedure for providing severance benefits at this time, if you incur a
Qualifying Termination prior to or on a Trigger Date, the Company will make severance payments to you in the form of continuation of your base salary in effect on the date of your separation from employment
(“Separation Date”) for twelve (12) months following the Separation Date. If you incur a Qualifying Termination after a Trigger Date, the Company will make severance payments to
you in the form of continuation of your base salary in effect on the Separation Date for six (6) months following the Separation Date. These payments will be made on the Company’s ordinary payroll dates, and will be subject to standard
payroll deductions and withholdings. 
  
 2. Health
Insurance. To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company’s current group health insurance policies, as of your termination from employment, you will be eligible to continue your
group health 

 insurance benefits. If you are eligible for and elect COBRA continuation coverage, the Company agrees to pay or reimburse
you in an amount equal to the amount of the health insurance premiums currently being paid by the Company on your behalf as of the date of this Agreement. These Company-paid amounts shall continue only so long as the period that you are actually
receiving severance payments under this Agreement. Later, you may be able to convert to an individual policy through the provider of the Company’s health insurance, if you wish. 
  
 3. Stock Options. To date, you have been granted options to purchase up to 412,740 shares of the Company’s
common stock, pursuant to the Company’s 2000 Stock Option Plan (the “Plan”). In the event of a Qualifying Termination prior to or on a Trigger Date, the Company agrees that all of your stock options will
immediately vest. In the event of a Qualifying Termination after a Trigger Date, the Company agrees that your stock options will continue to vest during the period that you are receiving severance benefits under Section 1 above. In any such
event, you shall have 12 months following the date of the final severance payment under this Agreement to exercise the vested portion of your stock options, after which time your options shall expire. Notwithstanding the above, in the event you
breach any material term of this Agreement or your Employee Inventions, Non-Competition, Non-Disclosure and Non-Solicitation Agreement with the Company (the “Non-Compete Agreement”), the continued vesting of
your stock options, if applicable, shall cease immediately as of the date of such breach and you shall immediately forfeit any right to exercise the stock options. In all other respects, the terms of the Plan and the applicable stock option
agreement(s) shall control. 
  
 4. Other Compensation or
Benefits. You acknowledge that, except as expressly provided in this Agreement, you will not receive any additional compensation, severance or benefits after the Separation Date. 
  
 5. Return of Company Property. By the Separation Date, you agree to
return to the Company all Company documents (and all copies thereof) and other Company property that you have had in your possession at any time, including, but not limited to, Company files, notes, drawings, records, business plans and forecasts,
financial information, specifications, computer- recorded information, tangible property (including, but not limited to, computers), credit cards, entry cards, identification badges and keys; and, any materials of any kind that contain or embody any
proprietary or confidential information of the Company (and all reproductions thereof). 
  
 6. Other Obligations. Both during and after your employment you will refrain from any unauthorized use or disclosure of the Company’s proprietary or confidential information or materials and agree to
comply with the terms of your Non-Compete Agreement with the Company. 
  
 7. Amendment to Non-Compete Agreement. In consideration of the severance and other benefits provided in this Agreement, the terms of your Non-Compete Agreement shall be amended as follows: 
  
 (a) Section 4(b) shall be deleted in its entirety and shall be
replaced with the following Section 4(b): 
  
 “For a period of 12 full months following the effective date of the termination of my employment with the Company, I will not, directly or indirectly, engage in, participate in, or assist, as owner, part-owner, partner, director,
officer, trustee, employee, agent or consultant, or in any other capacity, any business organization, anywhere in the world whose activities or products are directly or indirectly competitive with activities or products of the Company
(“Competing Activities”) without written consent from the Company (which consent will not be unreasonably withheld in those instances where such engagement, participation or assistance does not involve risk of
use or disclosure of Proprietary Information.” 
  

 2 

 (b) Section 4(c) shall be deleted in its entirety and shall be replaced with the following
Section 4(c): 
  
 “Intentionally
Omitted” 
  
 8. Confidentiality. The provisions of
this Agreement will be held in strictest confidence by you and the Company and will not be publicized or disclosed in any manner whatsoever; provided, however, that: (a) you may disclose this Agreement to your immediate
family; (b) the parties may disclose this Agreement in confidence to their respective attorneys, accountants, auditors, tax preparers, and financial advisors; (c) the Company may disclose this Agreement as necessary to fulfill standard or
legally required corporate reporting or disclosure requirements, including, but not limited to, disclosure in connection with due diligence conducted by or on behalf of any potential investor(s) in the Company or potential purchaser(s) of the
Company or substantially all of the assets of the Company; and (d) the parties may disclose this Agreement insofar as such disclosure may be necessary to enforce its terms or as otherwise required by law. In particular, and without limitation,
you agree not to disclose the terms of this Agreement to any current or former Company employee. 
  
 9. Nondisparagement. Following your termination from employment, both you and the Company agree not to disparage the other party, and the other
party’s officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that both you and the Company will respond accurately and fully
to any question, inquiry or request for information when required by legal process. 
  
 10. Release of Claims. In exchange for the payment of severance and the additional benefits provided with respect to equity hereunder at the time of your separation, you agree to enter into a waiver and general
release of legal claims against the Company and its affiliates and employees in a form satisfactory to the Company. 
  
 11. Miscellaneous. This Agreement constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with
regard to this subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This
Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure
to the 
  

 3 

 benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is
determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable. This Agreement
will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Maryland as applied to contracts made and to be performed entirely within Maryland. The parties submit to the jurisdiction of the
state and/or federal courts located in the county in the Company’s principal place of business. 
  
 12. Definitions. 
  
 (a) “Cause” for termination shall mean the occurrence, as reasonably determined by the Company’s Board of
Directors (the “Board”), of any one or more of the following events, circumstances or occurrences: (i) deliberate or willful refusal, failure or neglect to perform the material duties of your employment (other than by
reason of your physical or mental illness or impairment), including documented unsatisfactory performance of job duties as reasonably determined by the Board; (ii) your willful dishonesty, fraud, embezzlement or gross misconduct with respect to
the business or affairs of the Company that a reasonable person would consider damaging to the reputation of the Company or improper and unacceptable conduct by a senior executive of the Company; (iii) your indictment for or a conviction of or
entry of a plea not contesting the charge involving a felony or of any crime involving dishonesty or moral turpitude (as distinguished from a minor offense or minor traffic infraction); or (iv) your refusal to abide by or comply with the
reasonable documented directives of the Board. 
  
 (b)
“Good Reason” means shall mean either of the following events: 
  
 (i) A material reduction of your base salary or targeted bonus opportunity, or a material reduction of your authority, job duties or responsibilities to a level below that which would ordinarily be assigned to
an employee at your level without your prior written consent. 
  
 For purposes of this 12(b)(i), a “material reduction” shall mean (x) with respect to base salary or target bonus opportunity, any reduction in the amount of base salary and/or target bonus opportunity of 10% or more, and
(y) with respect to authority, job duties or responsibilities a material reduction in authority, job duties and responsibilities from such authority, job duties or responsibilities in effect as of the date hereof, excluding for this purpose an
isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by you. 
  
 (ii) A relocation of executive or the Company’s offices to a location more than fifty (50) miles from the
location at which you are performing your duties as of the date hereof. 
  
 [Signatures on Next Page] 
  

 4 

 If this Agreement is acceptable to you, please sign below and return the original to me. 
  
 Sincerely, 
  
 PANACOS PHARMACEUTICALS, INC. 
  

			
	By:	 	 /s/ Samuel Ackerman

	 	 	 Samuel Ackerman
 Chief Executive
Officer

  
 AGREED: 
  

	
	 /s/ Graham P. Allaway

	 Graham P. Allaway, Ph.D.

  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]